Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Immunology Right
  3. Omvoh (mirikizumab-mrkz) injection Right
  4. Is Omvoh™ (mirikizumab-mrkz) approved for the treatment of ulcerative colitis?
Search Omvoh (mirikizumab-mrkz) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Omvoh ® (mirikizumab-mrkz) injection

300 mg/15 mL, 100 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Is Omvoh™ (mirikizumab-mrkz) approved for the treatment of ulcerative colitis?

On October 26, 2023, the FDA approved Omvoh (mirikizumab) for the treatment of moderately to severely active ulcerative colitis in adults.

US_cFAQ_MIR105B_REGULATORY_APPROVAL_UC
US_cFAQ_MIR105B_REGULATORY_APPROVAL_UC
en-US

Regulatory Decisions

Mirikizumab also received approval for the treatment of ulcerative colitis in Japan, Canada, and the European Union in 2023.1,2

Regulatory decisions in additional markets around the world are expected in the coming months.1

Enclosed Prescribing Information

OMVOH™ (mirikizumab-mrkz) injection, for intravenous or subcutaneous use, Lilly

Reference

1FDA approves Lilly's Omvoh™ (mirikizumab-mrkz), a first-in-class treatment for adults with moderately to severely active ulcerative colitis. Press release. Eli Lilly and Company; October 26, 2023. Accessed October 27, 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class

2Lilly's Omvoh™ (mirikizumab) now available in Canada - a first-in-class treatment for adults with moderately to severely active ulcerative colitis. Press release. Eli Lilly and Company; October 16, 2023. Accessed November 1, 2023. https://www.lilly.ca/en-CA/news/press-releases/23.10.17-omvoh-colitis-NOC

Date of Last Review: October 27, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.43 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly